MAI Capital Management’s Definium Therapeutics DFTX Stock Holding History

MAI Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.95K	Buy	103 +44	+75%	+$747	﹤0.01%	3939
2025 Q4	$791	Buy	59 +49	+490%	+$606	﹤0.01%	3701
2025 Q3	$118	Hold	10	–	–	﹤0.01%	3734
2025 Q2	$65	Hold	10	–	–	﹤0.01%	3907
2025 Q1	$59	Hold	10	–	–	﹤0.01%	3381
2024 Q4	$70	Buy	+10	New	+$69	﹤0.01%	3443
2022 Q2	–	Sell	-880	Closed	-$15K	–	944
2022 Q1	$15K	Hold	880	–	–	﹤0.01%	897
2021 Q4	$18K	Buy	+880	New	+$28.1K	﹤0.01%	903

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MAI Capital Management's DFTX Position: Q1 2026 in Review

MAI Capital Management increased its Definium Therapeutics (DFTX) stake by 75% in Q1 2026, buying an estimated $747 and bringing the position to 103 shares worth $1.95K. The position accounts for ﹤0.01% of the portfolio, ranked #3939.

MAI Capital Management first reported a position in DFTX in Q4 2021 and has held it in 8 quarters since. The position peaked at $18K in Q4 2021. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

MAI Capital Management held 103 shares of Definium Therapeutics worth $1.95K as of Q1 2026.
MAI Capital Management bought 44 Definium Therapeutics shares in Q1 2026, an estimated $747.
Definium Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3939 holding.
MAI Capital Management first reported a position in Definium Therapeutics in Q4 2021 and has held it in 8 quarters since.
MAI Capital Management's Definium Therapeutics position peaked at $18K in Q4 2021.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.